Learn how doggybone DNA (dbDNA) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune responses without bacterial components.

Download the full article to learn:

• How dbDNA vaccines can match the immunogenicity of plasmid DNA without bacterial sequences.
• The potential of cell-free, scalable DNA vaccine production for cancer immunotherapy.
• Insights into the use of clinically relevant HPV antigens (E6 and E7) in DNA vaccine development.

This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS), the study demonstrates that dbDNA vaccines can elicit strong immune responses and broaden protection, particularly in cases where HA mutates but NA remains conserved.

Download the full article to learn:

• Insights into how combining HA and NA antigens can enhance the breadth and durability of influenza vaccine protection.
• The role of DNA targeting sequences in boosting immune responses within linear DNA vaccine platforms.
• The advantages of dbDNA technology for rapid, scalable, and cell-free vaccine production.

This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as “Doggybones.” These linear constructs, which exclude unnecessary bacterial elements, demonstrated equivalent gene expression and immune responses in preclinical models, offering a promising alternative for safer and scalable DNA vaccine production.

Download the full article to learn more about:

• How dbDNA  (Doggybone) constructs eliminate unwanted bacterial elements to enhance vaccine safety.
• How these novel constructs perform comparably to plasmids in both gene expression and immune response.
• Explore the potential for large-scale, enzymatic production of DNA vaccines without the need for bacterial culture.

CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers explore a promising alternative using dbDNA, an innovative linear DNA vector that could dramatically reduce manufacturing costs while eliminating safety concerns associated with traditional plasmid-based methods.

Download the full article to discover how scientists overcame initial technical challenges to successfully produce functional CAR19 T cells using this novel approach.

The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection and disease. The rise of the variants has also illustrated the need for the rapid evolution of vaccines, a niche that is well-suited for nucleic-acid-based vaccines. In this paper, two DNA vaccine approaches are compared: a conventional plasmid DNA vaccine and a novel, synthetic, linear DNA vaccine, comprising doggybone DNA. Both vaccines were protective in a small animal model of severe disease. Moreover, serum from animals vaccinated with SARS-CoV-2 DNA vaccines retained a level of neutralisation against multiple emerging variants.

Download the full article below.

As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and accessibility in gene and cell therapies. Touchlight’s innovative dbDNA technology offers an enzymatic alternative that’s efficient, scalable, and environmentally sustainable.

This article explores how dbDNA is reshaping DNA manufacturing and setting new sustainability standards by reducing water use, eliminating bacterial impurities, and minimizing waste. Learn how this pioneering approach unlocks a more sustainable future for genetic medicine.

What You’ll Learn:

• The impact of traditional pDNA production on environmental sustainability
• How dbDNA enables more efficient, scalable, and environmentally friendly manufacturing
• Why sustainable DNA production is vital to advancing gene and cell therapies

In this article, Jill Makin, Chief Scientific Officer at Touchlight, explores how synthetic DNA is revolutionising biomanufacturing across a wide range of genetic medicines, including DNA and mRNA vaccines, non-viral gene therapies, viral vectors for gene and cell therapies, and genome editing technologies.

The dbDNA Advantage

• Rapid, linear production scale-up
• High purity with no bacterial sequences
• Complex sequences up to 30kb
• Smaller manufacturing footprint
• FDA DMF and clinical adoption across modalities

As a leading provider of synthetic DNA, Touchlight supplies dbDNA to hundreds of biotech and pharmaceutical companies globally. Our robust IP portfolio and best-in-class production facilities ensure unparalleled quality and capacity.

We’re not stopping there. Touchlight is pioneering the future of DNA technology with breakthrough innovations like MegaBulb DNA (m-bDNA) for next-gen CRISPR gene editing. Access the article to learn more.